Close X
Get more out of WDDTY.com
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs
OR

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.


Click here if you're interested
Helping you make better health choices

What Doctors Don't Tell You

In shops now or delivered to your home from only £3.50 an issue!

Subscribe!
August 2019 (Vol. 4 Issue 6)

Drug companies wouldn't make a profit if they cured people, says Goldman Sachs
About the author: 
Bryan Hubbard

Drug companies wouldn't make a profit if they cured people, says Goldman Sachs image

Drug companies would stop being profitable if their drugs actually cured people—because they would lose their market. In fact, curing people is "an unsustainable business model," says merchant bank Goldman Sachs.

The bank is hesitant about investing in the emerging biotech industry because it's just too good at curing people.

Its gene therapy, which delivers 'one-shot cures', isn't sustainable because its market of sufferers would eventually disappear, warns the bank in an analysis of the sector. "While this proposition (of quick cures) carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow," one of the bank's analysts, Salveen Richter, writes in a note to clients.

He quotes the example of Gilead Sciences whose gene therapy for hepatitis C achieved cure rates of more than 90 per cent. The company's sales in the US for the treatment peaked at $12.5bn but have been falling since. Sales are predicted to be just $4bn this year.

The company is "a case in point where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," Richter writes. "In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines."

The bank advises the biotechs to focus on larger disease groups that continue to expand, such as haemophilia, which is growing at around 7 per cent a year, or look at diseases that have complications, such as spinal muscular atrophy (SMA), that affects the sufferer's ability to walk, eat or breathe, or to constantly innovate.


References

(Source: www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html)

You may also be interested in...

Support WDDTY

Help support us to hold the drugs companies, governments and the medical establishment accountable for what they do.

Advertisements

Latest Tweet

About

Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions..

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

© 2010 - 2019 WDDTY Publishing Ltd.
All Rights Reserved